EXPERT OPINION ON PHARMACOTHERAPY

Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives

Siponimod for the treatment of secondary progressive multiple sclerosis

Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients

Agomelatine for depression: expanding the horizons?

Current and emerging pharmacotherapy for emergency management of preeclampsia

Celecoxib for the treatment of musculoskeletal arthritis

Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes

Bivalirudin during percutaneous coronary intervention in acute coronary syndromes

Novel pharmacotherapy for burn wounds: what are the advancements

Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease

Current pharmacotherapeutic options for myasthenia gravis

Key considerations in the pharmacotherapy of tuberculous meningitis

Pharmacological management of sepsis in adults with a focus on the current gold standard treatments and promising adjunctive strategies: evidence from the last five years

Pharmacotherapy in body dysmorphic disorder: relapse prevention and novel treatments

Bazedoxifene for the treatment of osteoporosis

Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications

Current and promising therapy for primary biliary cholangitis

Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?

An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma

Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma

Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD-MBD)

Antimuscarinic drug therapy for overactive bladder syndrome in the elderly – are the concerns justified?

Pharmacotherapy for hypertension in pregnant patients: special considerations

Established and recent developments in the pharmacological management of urolithiasis: an overview of the current treatment armamentarium

An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents

Current state-of-the-art pharmacotherapy for the management of hepatitis B infection

An evaluation of tofacitinib for the treatment of psoriatic arthritis

Pharmacotherapeutic strategies for treating bronchiectasis in pediatric patients

An evaluation of masitinib for treating systemic mastocytosis

Is there an appropriate strategy for treating co-morbid irritable bowel syndrome and bladder pain syndrome?

Pharmacotherapy in inherited and acquired ventricular arrhythmia in structurally normal adult hearts

An update on the latest chemical therapies for reflux esophagitis in children

An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity

Roflumilast in patients with advanced chronic obstructive pulmonary disease: towards a better-targeted use

Zoledronic acid for the treatment of prostate cancer

An evaluation of enasidenib for the treatment of acute myeloid leukemia

Advances in pharmacotherapy of vestibular and ocular motor disorders

Pharmacology of new and developing intravenous therapies for the management of seizures and epilepsy

The efficacy and safety of luseogliflozin and sitagliptin depending on the sequence of administration in patients with type 2 diabetes mellitus: a randomized controlled pilot study

Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups

Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium?

The pharmacotherapeutic management of pediatric Crohn’s disease

Choosing an ideal pharmacotherapeutic strategy for dyslipidemia in children

An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes

How can pharmacotherapy impact the quality of life of individuals with high functioning autism?

What are the main challenges to the pharmacological management of cystinuria?

Challenges of selecting pharmacotherapy for macular edema the need for better and combination therapies